“The first AI-designed drugs have ended with disappointment.

Over the last year-plus, the first handful of molecules created by artificial intelligence have failed trials or been deprioritized. The AI companies behind these drugs brought them into the clinic full of fanfare about a new age of drug discovery — and have quietly shelved them after learning old lessons about how hard pharmaceutical R&D can be.”

Analyst Comment: While AI will no doubt disrupt some industries and work, the reach and impact of AI has been radically overhyped. These technologies are in the early stages of development and backers are quickly discovering their limitations, which are many.